Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients

This study reports in essential hypertensive patients the effect of 6 months treatment with olmesartan on plasma level of CGRP and number and survival of cEPCs. Methods and results: In 20 essential hypertensive patients treated with olmesartan medoxomil (20 mg per day for 6 months), cEPCs (CD34+KDR+, CD133+KDR+ and CD34+CD133+KDR+) (direct 3-color flow cytometry analysis), apoptosis of cEPCs (CD133+KDR+ cells with Annexin V expression), CGRP determination (ELISA) and HO-1 protein level (western blot) were assessed at baseline and after 3 and 6 months of treatments. Olmesartan normalized blood pressure (P 
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research